

ONCOLOGY ORDER FORM

oncology@paragonhealthcare.com

P: 855.505.2348 | F: 855.475.5865

A Carelon Company

PATIENT INFORMATION:

Patient N	lame:				[DOB:		Phone:	
MEDICAL INFORMATION									
ICD-10 co	de:	Diag	nosis:						
Allergies:									
	kg							BSA: m ²	
□ Call for	weight change	10% from	baseline				(if applicable)		
🗆 No dose	e modifications	required for a	ny weigh	t change					
LAB OF	RDERS OR C	THER TE	STS RE	LATED T	O TRE	ATME	NT		
□ CBC w/p	w/plts, diff 🛛 TSH			LVEF done:/Ejection				on fraction:%	
□ CMP									
LFTs Renal Function									
						ı by: 🗆 Infu	usion Center 🛛 Referring Provider		
HOLD PARAMETERS - PLEASE INDICATE									
□ No hold parameters for ANC/Platelets					No hold parameters				
□ Hold and		□ Hold and call for creatinine 1.5x ULN							
	call for ANC:		/Platelets:						
	ld parameters:			DC					
						lan al			
								Pepcid mg IV	
□ Reglan _	mg IV	□ Solu-Me	drol	_mg IV	🗆 Benad	lryl	mg PO	🗆 Tylenol mg PO	
Granisetron mg IV Hydration/other: Frequence							equency: [□ PRN □ Standing order □	
TREATMENT ORDER									
** All available drugs listed on Page 2**									
Date/Day	Drug		Dosing ., mg/kg)	Calculated Dose	Route	Fre	equency	Special Instructions *Volume, diluent, & rate set by Paragon unless otherwise noted here	
			<u> </u>						
	: infusion:			nber:					
Subsequent treatments may be given +/ days This order is good for cycles from the date ordered. Next appointment with Oncologist:									
Call referring provider for:									
Oral treatment patient is on:									
Other orde	rs/information:								
PROVID	DER INFORM	ATION							
	form and utilizing our s g with medical and pres							ior authorization and specialty pharmacy designated	
Provider Name:			Signature:			2:		Date:	
Provider Name: Phone: Phone:			F	ax:		Con	ntact Person:		
PREFE	RRED LOCA	TION							
City:		St	ate:		View	v our lo	cations l	here:	
				PARAGONHEA	LTHCARE.CO	ОМ			

IMPORTANT NOTICE: This fax is intended to be delivered only to the named address and contains material that is confidential, privileged property, or exempt from disclosure under applicable law. If you are not the named addressee, you should not disseminate, distribute, or copy this fax. Please notify the sender immediately and destroy all copies if you have received this document in error.





COMPREHENSIVE SUPPORT FOR ONCOLOGY THERAPY

rituximab & biosimilars

trastuzumab & biosimilars

toripalimab

tremelimumab

triptorelin pamoate

A Carelon Company

atezolizumab& hyaluronidase

daratumumab & hyaluronidase

bevacizumab & biosimilars

cemiplimab

denosumab

dostarlimab

PATIENT INFORMATION:

PATIENT INFORMATION:								
Patient Name:	DOB:							
REQUIRED DOCUMENTATION	I FOR REFERRAL PRO	CESSING & INSURANCE APPROVAL						
□ Patient demographics including insurance information (copies of insurance cards preferred)								
Treatment orders - include drugs,	dose, frequency, administra	ation, and cycle definition						
Pre-medication orders (including	glucocorticoids) - <i>if applica</i>	ble						
Supportive therapy orders (including anti-emetics, CSFs, hydration, antibiotics) - <i>if applicable</i>								
□ Note: oral prescriptions need to b	e filled at local pharmacy pr	rior to infusion						
Monitoring and hold parameters								
\Box Dose adjustment protocol, where applicable (i.e., weight changes, lab parameters)								
\Box Standing orders (infusion reactions, management of CVC occlusion, etc.)								
Lab orders - if labs need to be drawn by Paragon								
Clinical chart notes within the last 12 months								
Recent lab results & diagnostic results								
Medication list, if available								
Date of last cycle or infusion dose								
Next follow-up visit with Oncolog	ist							
Oncology Therapies Available:								
amivantamab	fulvestrant	pembrolizumab						
alvelumab	goserelin acetate	pertuzumab						
atezolizumab	ipilimumab	pertuzumab/trastuzumab/hyaluronidase						

durvalumab pegfilgrastim Paragon Healthcare will complete insurance verification and submit all required documentation for approval to the patient's insurance company for eligibility. Our team will notify you if any additional information is required. We will review financial responsibility with the patient and refer him/her to any available co-pay assistance as needed. Thank you for the referral.

lantreotide

nivolumab

octreotide

leuprolide acetate

nivolumab & relatimab

mogamulizumab

Please fax all information to (855) 475-5865 or call (855) 505-2348 for assistance

PARAGONHEALTHCARE.COM

IMPORTANT NOTICE: This fax is intended to be delivered only to the named address and contains material that is confidential, privileged property, or exempt from disclosure under applicable law. If you are not the named addressee, you should not disseminate, distribute, or copy this fax. Please notify the sender immediately and destroy all copies if you have received this document in error.